DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $524M
- 88 holdings
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
AUM over time
Book
| XBI, SPDR SP Biotech ETF | Reduce −7.7% | 566,000 | $79.32 | $45M | −47,000 | −$633K | |
| STXS, Stereotaxis | Hold | 13,680,554 | $1.80 | $25M | — | — | |
| Blueprint Medicines | Reduce 0.0% | 261,235 | $65.89 | $17M | −45 | +$4M | |
| BHVN, Biohaven | Hold | 110,100 | $151.17 | $17M | — | — | |
| ASND, Ascendis Pharma A/s | Reduce −2.5% | 135,712 | $103.26 | $14M | −3,500 | +$1.1M | |
| XENE, Xenon Pharmaceuticals | Reduce −14.5% | 375,223 | $36.10 | $14M | −63,400 | +$203K | |
| Adicet Bio | Hold | 935,766 | $14.22 | $13M | — | — | |
| FATE, Fate Therapeutics | Reduce −2.0% | 539,940 | $22.41 | $12M | −11,000 | −$1.6M | |
| NDAQ, Nasdaq Omx | Hold | 102,500 | $116.96 | $12M | — | — | |
| RVMD, Revolution Medicines | Add +60.0% | 479,785 | $19.72 | $9.5M | +180,000 | +$3.6M | |
| CYTK, Cytokinetics | Reduce −13.0% | 183,995 | $48.45 | $8.9M | −27,500 | +$605K | |
| SNDX, Syndax Pharmaceuticals | Reduce −4.2% | 355,487 | $24.03 | $8.5M | −15,500 | +$1.4M | |
| NBIX, Neurocrine Biosciences | Reduce −3.0% | 80,155 | $106.21 | $8.5M | −2,500 | +$456K | |
| IDYA, Ideaya Biosciences | Reduce −1.8% | 538,561 | $14.92 | $8M | −10,000 | +$465K | |
| EWTX, Edgewise Therapeutics | Add +12.2% | 781,112 | $9.84 | $7.7M | +85,153 | +$2.1M | |
| NRIX, Nurix Therapeutics | Hold | 566,695 | $13.03 | $7.4M | — | — | |
| Iveric Bio | Reduce −0.2% | 401,476 | $17.94 | $7.2M | −1,000 | +$3.3M | |
| Sage Therapeutics | Hold | 180,306 | $39.16 | $7.1M | — | — | |
| Karuna Therapeutics | Reduce −53.4% | 28,886 | $224.92 | $6.5M | −33,167 | −$1.4M | |
| Cymabay Therapeutics | Reduce −4.7% | 1,703,235 | $3.50 | $6M | −84,334 | +$688K | |
| DXCM, DexCom | Hold | 72,552 | $80.54 | $5.8M | — | — | |
| Merus | Add +5.3% | 276,893 | $20.03 | $5.5M | +14,002 | −$406K | |
| Morphic | Hold | 195,467 | $28.30 | $5.5M | — | — | |
| ALEC, Alector | Reduce −3.6% | 532,438 | $9.46 | $5M | −20,000 | −$576K | |
| Mirati Therapeutics | Reduce −10.1% | 71,600 | $69.85 | $5M | −8,000 | −$343K | |
| IPSC, Century Therapeutics | Hold | 475,367 | $9.89 | $4.7M | — | — | |
| RCUS, Arcus Biosciences | Reduce −4.8% | 178,717 | $26.16 | $4.7M | −9,000 | −$82K | |
| Aerie Pharmaceuticals | Add +6.3% | 307,232 | $15.13 | $4.6M | +18,192 | +$2.5M | |
| APLS, Apellis Pharmaceuticals | Reduce −32.0% | 65,946 | $68.30 | $4.5M | −30,989 | +$121K | |
| Cardiovascular Systems | Hold | 286,988 | $13.86 | $4M | — | — | |
| AXGN, Axogen | Hold | 332,103 | $11.92 | $4M | — | — | |
| 89bio | Reduce −14.6% | 654,862 | $5.79 | $3.8M | −111,912 | +$1.3M | |
| Kalvista Pharmaceuticals | Reduce −3.9% | 255,313 | $14.51 | $3.7M | −10,350 | +$1.1M | |
| F-Star Therapeutics | Hold | 576,881 | $5.12 | $3M | — | — | |
| BCYC, Bicycle Therapeutics | Reduce −6.9% | 122,200 | $23.26 | $2.8M | −9,000 | +$640K | |
| KURA, Kura Oncology | Add +75.1% | 206,329 | $13.66 | $2.8M | +88,500 | +$658K | |
| ATRC, Atricure | Hold | 72,029 | $39.10 | $2.8M | — | — | |
| Mersana Therapeutics | Reduce −7.1% | 377,763 | $6.76 | $2.6M | −29,000 | +$675K | |
| Mediwound | New | 1,428,571 | $1.39 | $2M | +1,428,571 | +$2M | |
| Vigil Neuroscience | Add +116.9% | 216,395 | $9.10 | $2M | +116,641 | +$1.7M | |
| ARAY, Accuray | Hold | 941,800 | $2.08 | $2M | — | — | |
| Iteos Therapeutics | Reduce −7.3% | 97,560 | $19.05 | $1.9M | −7,738 | −$310K | |
| LRMR, Larimar Therapeutics | Add +1050.1% | 574,996 | $3.20 | $1.8M | +525,000 | +$1.7M | |
| LKFT, Galapagos | Hold | 42,675 | $42.65 | $1.8M | — | — | |
| Syros Pharmaceuticals | New | 265,878 | $6.44 | $1.7M | +265,878 | +$1.7M | |
| Dice Therapeutics | Reduce −50.0% | 78,500 | $20.28 | $1.6M | −78,404 | −$843K | |
| VKTX, Viking Therapeutics | Add +19.5% | 552,400 | $2.72 | $1.5M | +90,000 | +$167K | |
| Keros Therapeutics | Hold | 39,000 | $37.62 | $1.5M | — | — | |
| Affimed | Hold | 686,282 | $2.06 | $1.4M | — | — | |
| ORIC, Oric Pharmaceuticals | Reduce −0.6% | 413,526 | $3.20 | $1.3M | −2,400 | −$540K | |
| Surface Oncology | Hold | 1,100,000 | $1.04 | $1.1M | — | — | |
| AUTL, Autolus Therapeutics | Hold | 496,150 | $2.14 | $1.1M | — | — | |
| Neuronetics | Hold | 313,717 | $3.18 | $998K | — | — | |
| NGM Biopharmaceuticals | Reduce −30.4% | 74,953 | $13.07 | $980K | −32,700 | −$400K | |
| Gamida Cell | New | 614,896 | $1.59 | $978K | +614,896 | +$978K | |
| BHVN, Biohaven | New | 153,564 | $6.30 | $967K | +153,564 | +$967K | |
| SCYX, Scynexis | Reduce −12.2% | 399,064 | $2.40 | $958K | −55,428 | +$113K | |
| Mereo Biopharma Group | Hold | 1,096,513 | $0.8609 | $944K | — | — | |
| Regulus Therapeutics | Hold | 555,555 | $1.70 | $944K | — | — | |
| Kinnate Biopharma | Reduce −65.2% | 78,074 | $11.95 | $933K | −146,377 | −$1.9M | |
| Pardes Biosciences | Add +6.3% | 479,386 | $1.85 | $887K | +28,281 | −$498K | |
| BWAY, Brainsway | Add +10.0% | 220,000 | $3.61 | $794K | +20,000 | −$172K | |
| Genfit | Hold | 187,940 | $3.65 | $686K | — | — | |
| Holding | Hold | 1,767,146 | $0.3865 | $683K | — | — | |
| GH Research | Reduce −4.3% | 52,631 | $11.63 | $612K | −2,369 | +$63K | |
| Medicenna Therapeutics | New | 660,000 | $0.8303 | $548K | +660,000 | +$548K | |
| BDTX | Hold | 313,600 | $1.69 | $530K | — | — | |
| Nextcure | Hold | 187,696 | $2.75 | $516K | — | — | |
| CMPS, Compass Pathways | Reduce −36.7% | 47,390 | $10.72 | $508K | −27,500 | −$302K | |
| PRQR, Proqr Therapeutics | New | 649,383 | $0.7438 | $483K | +649,383 | +$483K | |
| Theseus Pharmaceuticals | Hold | 81,899 | $5.80 | $475K | — | — | |
| Sutro Biopharma | Reduce −4.1% | 81,200 | $5.55 | $451K | −3,500 | +$10K | |
| Ikena Oncology | New | 122,517 | $3.55 | $435K | +122,517 | +$435K | |
| Otonomy | Hold | 1,470,199 | $0.2952 | $434K | — | — | |
| CMPX, Compass Therapeutics | Reduce −5.0% | 188,094 | $2.28 | $429K | −10,000 | −$96K | |
| Venus Concept | Hold | 968,187 | $0.4400 | $426K | — | — | |
| Masimo | Hold | 3,000 | $141.00 | $423K | — | — | |
| Adaptimmune Therapeutics | Hold | 351,064 | $1.07 | $377K | — | — | |
| INGN, Inogen | Hold | 15,000 | $24.27 | $364K | — | — | |
| Macrogenics | Reduce −47.9% | 100,000 | $3.46 | $346K | −92,000 | −$220K | |
| BMEA, Biomea Fusion | Reduce −74.7% | 34,625 | $9.79 | $339K | −102,310 | −$1.3M | |
| Spero Therapeutics | New | 125,000 | $2.00 | $250K | +125,000 | +$250K | |
| Holding | Hold | 140,000 | $1.13 | $158K | — | — | |
| Reunion Neuroscience | New | 96,585 | $1.43 | $138K | +96,585 | +$138K | |
| Compugen | Hold | 205,202 | $0.6579 | $135K | — | — | |
| Phasebio Pharmaceuticals | Reduce −15.0% | 321,856 | $0.1771 | $57K | −56,755 | −$170K |
Showing top 50 of 86 by value
Exits / last held
Gone since 2022 Q2, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Natus Medical | Exit | 0 | $32.77 | $4.7M | −143,600 | −$4.7M | |
| Holding | Exit | 0 | $75.25 | $3.6M | −48,452 | −$3.6M | |
| TCOM, Field Trip Health | Exit | 0 | $0.8403 | $1.6M | −1,904,141 | −$1.6M | |
| WVE, Wave Life Sciences | Exit | 0 | $3.25 | $1.2M | −372,361 | −$1.2M | |
| Radius Health | Exit | 0 | $10.37 | $953K | −91,935 | −$953K | |
| Rigel Pharmaceuticals | Exit | 0 | $1.13 | $441K | −390,066 | −$441K | |
| Lava Therapeutics | Exit | 0 | $2.95 | $379K | −128,335 | −$379K | |
| MDGL, Madrigal Pharmaceuticals | Exit | 0 | $71.61 | $222K | −3,100 | −$222K | |
| Connect Biopharma | Exit | 0 | $0.8720 | $218K | −250,000 | −$218K | |
| Aslan Pharmaceuticals | Exit | 0 | $0.4946 | $170K | −343,720 | −$170K | |
| ANNX, Annexon | Exit | 0 | $3.77 | $154K | −40,796 | −$154K |
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site, 2021 Q3 to 2026 Q2